Hints and tips:
Related Special Reports
Related Topics
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Kasim Kutay, Novo Holdings chief executive and a Novo Nordisk board member, told the Financial Times that rising income from its 28 per cent stake in Novo Nordisk and other investments would give his fund...
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...But she said if Novo Nordisk could develop such a treatment, it would be “ideal”....
...He said Novo Nordisk was facing a “similar challenge” as some of the companies selling advanced therapies....
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...A new study by Novo Nordisk has shown that its blockbuster drug Ozempic cut the risk of death, disease progression and cardiovascular issues by 24 per cent for patients with type 2 diabetes and chronic kidney...
...Novo Nordisk shares have hit a new record after the Danish drugmaker revealed early stage results for a new weight loss pill that offers better results than its blockbuster Wegovy....
...Novo Nordisk is the second-ever European company to achieve a $500bn market value following LVMH last April....
...However, the plants will not enable Novo Nordisk to ramp up production until 2026....
...Novo Nordisk’s blockbuster weight loss drugs powered the company to record a 36 per cent increase in sales last year....
...I don’t think shareholders of Novo Nordisk, now Europe’s most valuable company and celebrating a century of profitable growth, would agree....
...Ozempic” takes, referring to the diabetes and obesity medicine produced by Eli Lilly’s rival in the category, Novo Nordisk....
...Danish drugmaker Novo Nordisk has been “surprised” by the readiness of European consumers to pay for weight-loss drugs from their own pockets, as the region’s largest company invests in new supply to meet...
...Novo Holdings owns 28 per cent of the shares in Novo Nordisk but has 77 per cent of the voting rights....
...Eli Lilly, maker of Mounjaro and the recently approved Zepbound, and Novo Nordisk have so far dominated the sector....
...“Once it is complete, which we anticipate around the end of 2024, Novo Nordisk will honour all existing contracts,” the company told the FT on Tuesday. Novo Holdings declined to comment....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...It also ensured Novo Nordisk was not for sale. “So not even Elon Musk in a wild night could take over or attempt to take over Novo Nordisk,” he says....
...Like Novo Nordisk’s Wegovy and Ozempic, Viking’s VK2735 mimics the GLP-1 hormone that can suppress appetite....
...The deals are the first signed under a collaboration between Novo Nordisk and Flagship Pioneering in May 2022....
...Earlier this month, Novo Nordisk lifted full-year revenue and profits guidance because of the better than expected sales....
...Read more about Novo Nordisk here....
International Edition